USCIB Urges Administration to Remove China Tariffs on Products Needed to Fight COVID-19

USCIB submitted comments to the United States Trade Representative (USTR) on China tariffs on May 18. The comments focused on Additional Modifications to the 301 Action to Address COVID-19 in relation to China’s acts, policies and practices related to technology transfer, intellectual property and innovation.

As noted in previous comments that USCIB has submitted on 301 actions, USCIB continues to hold the position that tariffs stifle the U.S. economy and will not achieve the Administration’s goal of changing China’s behavior.

“Rather than creating more opportunities for U.S. business, sweeping tariffs restrict U.S. agriculture, goods, and services exports and raise costs for businesses and consumers,” said USCIB Senior Director for Investment, Trade and Financial Services Eva Hampl. The economic crisis caused by the COVID-19 pandemic has amplified the negative impacts of the tariffs on companies’ supply chains and the U.S. economy.”

USCIB highlighted several products that should be removed from the tariff list, including medical equipment central to the diagnosis and treatment of COVID-19 response and of related ailments, as well as medical equipment parts, components and 3D printers.

The comments also highlight chemicals and plastics, which have been recognized for their critical role in the production of cleaning and disinfecting products, as well as medical equipment such as masks, diagnostic equipment and disposable gowns.

For a complete list of products and USCIB’s comments to USTR, please click here, please click here.

Staff Contact:   Alice Slayton Clark

Director, Investment, Trade and China
Tel: 202.682.0051

Related Content